Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article outlines how patient safety is integrated into the healthcare system, focusing on quality improvement and processes such as error reporting and root cause analysis, specifically for dermatologists.

This study found that users of a German direct-to-consumer teledermatology platform for finasteride reported improvements in hair appearance and self-esteem, though 12% experienced treatment-related adverse events.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

Low-dose oral minoxidil is safe for treating hair loss, especially in women, with side effects stopping after use ends.

This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

In this randomized controlled study, topical Flutamide 1% gel, applied twice daily for eight weeks, significantly reduced papules and pustules in patients with mild to moderate acne vulgaris compared to baseline.

This study found that patients with vitiligo in the United States had higher rates of autoimmune conditions, infections, and skin cancer compared to matched controls, with higher vitiligo prevalence in Asian and Hispanic populations.

The study found that both mometasone and calcipotriol ointments effectively reduced alopecia severity in localized alopecia areata, with calcipotriol having fewer side effects, while tacrolimus showed no significant effect.

This study found that baricitinib, taken for 24 weeks, significantly reduced alopecia severity in patients with moderate-to-severe alopecia areata, with 50% showing marked improvement and overall favorable safety and efficacy reported.

The study found that patients over 70 with advanced ovarian cancer may have better overall and progression-free survival with weekly paclitaxel-carboplatin chemotherapy compared to a three-weekly regimen, despite increased blood-related toxicities.

Baricitinib is a safe and effective treatment for severe alopecia areata.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.

This study found that in Japanese male patients with androgenetic alopecia, dutasteride 0.5 mg daily over 52 weeks was associated with improvements in hair growth and appearance, with reported adverse events mostly mild.

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This abstract discusses the efficacy of spironolactone, cyproterone acetate, and flutamide in treating female pattern hair loss, noting that flutamide use requires caution due to potential liver toxicity, especially at high doses.

This review discusses the side effects and monitoring guidelines for commonly prescribed systemic acne treatments and reports no new clinical findings.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

This study reviewed the safety of JAK inhibitors for alopecia areata, finding that common side effects included headache and acne, with varying risks for respiratory infections and no increased risk of serious adverse events.

In this study, 33 overweight women with normal hormone levels but showing PCOS symptoms experienced substantial reductions in acne lesions and improvements in hirsutism and menstrual irregularities after 8 weeks of Tracnil™ treatment, with minimal adverse reactions reported.

This study followed 152 patients undergoing hair transplant surgery, reporting that 86.18% experienced excellent results after one year, despite temporary complications like forehead swelling in 69.74% of participants, suggesting the procedure's relative safety and effectiveness for androgenetic alopecia.

In this study, researchers analyzed adverse event reports from the FAERS database to identify safety concerns associated with ipilimumab in elderly patients, noting common issues like gastrointestinal events and new signals such as orchitis and alopecia areata, with timing influenced by body weight.

In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.

Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.

Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.